FDA Announces an Analgesic Clinical Trial Designs, Extrapolation, and Endpoints in Patients from Birth to Less Than Two Years of Age Public Workshop

1 messages 1 people Latest: Oct 06, 2021
The U.S. Food and Drug Administration (FDA)'s Division of Pediatrics and Maternal Health (DPMH) in collaboration with the Division of Anesthesiology, Addiction Medicine, and Pain Medicine (DAAP) and the University of Maryland CERSI, is announcing a 2-day public workshop, "Analgesic Clinical Trial Designs, Extrapolation, and Endpoints in Patients from Birth to Less Than Two Years of Age" on October 13-14, 2021. The purpose of the public workshop is to discuss the current state of therapies to treat acute pain in children, identify data gaps, and consider methods to improve the current drug development paradigm for acute pain in patients less than 2 years of age (e.g., use of pediatric extrapolation, and novel clinical trial designs). The workshop is intended to focus on drugs with well-established mechanisms of action (NSAIDs, acetaminophen, local anesthetics, and opioids). Workshop Information: The public workshop will be held on the following dates and times: Day 1: October 13, 2021 (10:00 am - 1:30 pm EST) Day 2: October 14, 2021 (10:00 am - 3:00 pm EST) The public workshop will be held in virtual format only. Please note that due to the impact of this COVID-19 pandemic, all meeting participants will be joining this public meeting via an online teleconferencing platform. Webcast: Registrants will receive webcast information once registered. Agenda and Registration: To access the agenda and registration for the public workshop, visit the following website: https://urldefense.com/v3/__https:/lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDAsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMTA5MjQuNDY0MjYzNTEiLCJ1cmwiOiJodHRwczovL2NlcnNpLnVtZC5lZHUvZXZlbnQvMTY1NTcvYW5hbGdlc2ljLWNsaW5pY2FsLXRyaWFsLWRlc2lnbnMtZXh0cmFwb2xhdGlvbi1hbmQtZW5kcG9pbnRzLWluLXBhdGllbnRzLWZyb20tYmlydGgtdG8tdW5kZXItYWdlLTI_dXRtX21lZGl1bT1lbWFpbCZ1dG1fc291cmNlPWdvdmRlbGl2ZXJ5In0.hwEa90NQWuDtoJQAUh0U3U5gKC-JgdhQEbaLqg0TWE8/s/1255637289/br/112882137129-l__;!!KDurfCY!uo9EvEUSTyP9MrsrdkvgQwST-YY-OXA-b-t1b8DDNJxsJkaGmrKjjDQNaM9hor07mg$. There is no registration fee to attend this public workshop. If you have any additional questions about this workshop, please contact Lily Mulugeta at [email protected]<mailto:[email protected]>. Best regards, Lily Mulugeta, PharmD Associate Director, Policy and Research Division of Pediatrics and Maternal Health, ORPURM Office of New Drugs Center for Drug Evaluation and Research U.S. Food and Drug Administration